10-Q: Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Zevra Therapeutics reports a net loss of $33.2 million for the third quarter of 2024, alongside updates on its commercial and clinical programs.

Summary

• Zevra Therapeutics reported a net loss of $33.2 million for the three months ended September 30, 2024, compared to a net loss of $10.4 million for the same period in 2023.
• The company's revenue for the quarter was $3.7 million, an increase from $2.9 million in the prior year, primarily driven by royalties and EAP reimbursements.
• Operating expenses totaled $27.2 million, with research and development at $10.9 million and selling, general, and administrative expenses at $16.2 million.
• The company recognized a $2.0 million charge related to inventory obsolescence.
• Other expenses included a $2.3 million interest expense and a $4.7 million loss from fair value adjustments related to warrant and CVR liabilities.
• For the nine months ended September 30, 2024, the net loss was $69.8 million, compared to $26.2 million in 2023.
• The company's cash, cash equivalents, and investments totaled $95.5 million as of September 30, 2024.
• Zevra believes its existing cash will fund operations into 2027, subject to debt covenant compliance.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the FDA approval of MIPLYFFA and the company's cash runway into 2027 are positive, the significant net loss, increased operating expenses, and the legal dispute with Commave are concerning. The company's reliance on future product sales and potential capital raises also adds uncertainty.

Positives

• The company's revenue increased to $3.7 million in the third quarter of 2024, up from $2.9 million in the same period last year.
• MIPLYFFA received FDA approval on September 20, 2024, and the company received a transferable rare pediatric disease priority review voucher.
• Zevra believes its existing cash will fund operations into 2027, subject to debt covenant compliance.
• The company has a $100 million term loan facility with $60 million funded on April 5, 2024, and the remaining $40 million available in tranches.
• The company has a 2024 ATM agreement for up to $75 million in share sales.

Negatives

• The company reported a net loss of $33.2 million for the third quarter of 2024, a significant increase from the $10.4 million loss in the same period of 2023.
• The company recognized a $2.0 million charge related to inventory obsolescence.
• The company's operating expenses increased to $27.2 million for the quarter.
• The company experienced a $4.7 million loss from fair value adjustments related to warrant and CVR liabilities.
• The company's net loss for the nine months ended September 30, 2024, was $69.8 million, compared to $26.2 million in 2023.

Risks

• The company's recurring operating losses and negative cash flows raise substantial doubt about its ability to continue as a going concern.
• The company's ability to continue operating as a going concern is contingent upon its ability to generate revenue from approved products or obtain product candidate regulatory approvals.
• The company may need to obtain additional financing to fund its operations.
• The company is involved in a legal dispute regarding the AZSTARYS License Agreement, which could have an adverse impact on the company's business.
• The company's debt obligations may be accelerated upon customary events of default, including non-payment of principal, interest, fees and other amounts, covenant defaults, insolvency, material judgments, or inaccuracy of representations and warranties.

Future Outlook

The company believes its existing cash, cash equivalents, and investments will be sufficient to fund operations into 2027, subject to continuing compliance with debt covenants. The company intends to use the net proceeds of the August 2024 offering to support the commercial launch of MIPLYFFA, continued commercial support for OLPRUVA, and the continued development of celiprolol and KP1077.

Management Comments

• The company is focused on bringing life-changing therapeutics to people living with rare diseases.
• The company is executing on a balanced approach by building a culture that is patient-focused and driven by our commitment to developing and making available therapies which address the myriad unmet needs within the rare disease community.
• The company is seeking to further expand its pipeline through both internal development and through business development activities to collaborate, partner, and potentially acquire additional assets.
• The company intends to target assets that will allow it to leverage the expertise and infrastructure that it has built to help mitigate risk and enhance its probability of success.

Industry Context

This announcement comes as Zevra Therapeutics continues to establish itself as a key player in the rare disease therapeutics market. The FDA approval of MIPLYFFA is a significant milestone, and the company's focus on commercializing both MIPLYFFA and OLPRUVA positions it to compete with other companies in the rare disease space. The company's pipeline, including celiprolol and KP1077, also indicates a commitment to long-term growth and innovation in this sector.

Comparison to Industry Standards

• Zevra's third-quarter net loss of $33.2 million is significant, especially when compared to other commercial-stage biotech companies. For example, companies like BioMarin Pharmaceutical Inc. and Sarepta Therapeutics, while also experiencing losses, often have higher revenue streams from established products.
• The company's revenue of $3.7 million is relatively low compared to other companies with commercial products. For instance, companies like Ultragenyx Pharmaceutical Inc. and Horizon Therapeutics (now part of Amgen) have much higher revenue from their rare disease products.
• The company's cash position of $95.5 million is moderate, and while it is projected to fund operations into 2027, it is essential to monitor cash burn and potential future capital needs. Companies like Global Blood Therapeutics (acquired by Pfizer) and Alexion Pharmaceuticals (acquired by AstraZeneca) had significantly larger cash reserves before their acquisitions.
• The FDA approval of MIPLYFFA is a major achievement, placing Zevra in a similar position to companies like Catalyst Pharmaceuticals and Retrophin (now Travere Therapeutics) that have successfully brought rare disease treatments to market. However, the commercial success of MIPLYFFA will be crucial for Zevra's long-term viability.
• The company's pipeline, including celiprolol and KP1077, is promising, but the clinical development timelines and regulatory hurdles are significant. Companies like Vertex Pharmaceuticals and Alnylam Pharmaceuticals have demonstrated success in advancing novel therapies, but they also have substantial resources and experience.

Legal Proceedings

• The company is engaged in a legal dispute with Commave regarding the AZSTARYS License Agreement.
• Commave filed a complaint against Zevra in the Court of Chancery of the State of Delaware alleging breach of contract and seeking injunctive relief, specific performance, declaratory relief, and damages.
• Zevra filed a motion to dismiss the complaint on October 7, 2024.

Stakeholder Impact

• Shareholders may be concerned about the company's significant net loss and the legal dispute with Commave.
• Employees may be affected by the company's restructuring and closure of laboratory facilities.
• Patients with rare diseases may benefit from the company's development and commercialization of new therapies.
• Creditors may be concerned about the company's ability to meet its debt obligations.

Next Steps

• The company will focus on the commercial launch of MIPLYFFA.
• The company will continue commercial support for OLPRUVA.
• The company will continue the development of celiprolol and KP1077.
• The company will evaluate strategic alternatives to advance clinical development toward NDA submission and later, commercialization for KP1077.
• The company will seek regulatory approval for MIPLYFFA in the EU.
• The company will continue to monitor developments in the legal dispute with Commave.

Key Dates

Keywords

Zevra Therapeutics, MIPLYFFA, OLPRUVA, arimoclomol, sodium phenylbutyrate, celiprolol, KP1077, AZSTARYS, rare diseases, financial results, clinical trials, FDA approval, commercialization, Niemann-Pick disease type C, urea cycle disorders, Vascular Ehlers-Danlos syndrome, idiopathic hypersomnia, narcolepsy